Research programme: small molecule drug conjugate cancer therapeutics - Molecular Targeting Technologies/National Health Research Institutes

Drug Profile

Research programme: small molecule drug conjugate cancer therapeutics - Molecular Targeting Technologies/National Health Research Institutes

Alternative Names: DPA-drug conjugates; Small molecule drug conjugate; SMDC; SMDC-T1; Synthetic zinc-dipicolylamine; T1; Zn-DPA drug conjugates; Zn-DPA-SN 38 conjugate

Latest Information Update: 07 Aug 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Molecular Targeting Technologies; National Health Research Institutes
  • Class Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Aug 2014 Research programme: small molecule drug conjugate cancer therapeutics - Molecular Targeting Technologies/National Health Research Institutes is available for licensing in World as of 07 Aug 2014. http://www.mtarget.com
  • 05 Aug 2014 Preclinical trials in Cancer in Taiwan (unspecified route)
  • 05 Aug 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top